Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 13INDUSTRY 5NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 15Other hematologic neoplasm 14Lymphoid 13Gynecologic 10Genitourinary 7Dermatologic 7CNS 7Plasma cell 5Other solid neoplasm 4Gastrointestinal 4Thoracic 3Head & Neck 2Breast 2Tumor-Agnostic 1Myeloid 1Classical hematology 1

Conditions

Breast Neoplasms 2Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 80Paclitaxel 53Trastuzumab 41Tamoxifen 40Doxorubicin 39Specimen Handling 35Docetaxel 35Magnetic Resonance Spectroscopy 34Radiotherapy 33Taxes 30Fluorouracil 26Chemotherapy, Adjuvant 26Carboplatin 24Epirubicin 22Biopsy 22Filgrastim 21Neoadjuvant Therapy 19Methotrexate 19aldesleukin 17Peripheral Blood Stem Cell Transplantation 16Bevacizumab 14Anastrozole 14exemestane 13Lapatinib 13veliparib 12CMF regimen 12sargramostim 11Goserelin 11Fulvestrant 11Capecitabine 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Sirolimus × Breast × Clear all
NCT00376688 2020-02-24

Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
31 enrolled 5 charts
Breast

Breast Neoplasms

NCT00699491 2018-06-13

Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
48 enrolled 14 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡